Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-"ß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors. It also develops ENV 105, an antibody that targets CD105/Endoglin, which expressed in tumor cells and surrounding cells; and ENV 205, an antibody that targets mitochondrial DNA. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California. more
Time Frame | KAPA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -37.42% | 0.49% | -1.93% |
1-Month Return | -41.57% | -3.1% | -3.69% |
3-Month Return | -34.01% | -8.59% | 0.82% |
6-Month Return | -62.69% | -4.57% | 3.51% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Profit | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 1.05M | 1.94M | 571.00K | 1.71M | [{"date":"2020-12-31","value":53.83,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":29.39,"profit":true},{"date":"2023-12-31","value":88.21,"profit":true}] | |
Operating Income | (1.05M) | (1.94M) | (571.00K) | (1.71M) | [{"date":"2020-12-31","value":-104600000,"profit":false},{"date":"2021-12-31","value":-194300000,"profit":false},{"date":"2022-12-31","value":-57100000,"profit":false},{"date":"2023-12-31","value":-171400000,"profit":false}] | |
Total Non-Operating Income/Expense | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (1.05M) | (2.15M) | (1.05M) | (1.81M) | [{"date":"2020-12-31","value":-105141100,"profit":false},{"date":"2021-12-31","value":-214500000,"profit":false},{"date":"2022-12-31","value":-105000000,"profit":false},{"date":"2023-12-31","value":-181200000,"profit":false}] | |
Income Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | (1.05M) | (2.15M) | (1.05M) | (1.81M) | [{"date":"2020-12-31","value":-105141100,"profit":false},{"date":"2021-12-31","value":-214500000,"profit":false},{"date":"2022-12-31","value":-105000000,"profit":false},{"date":"2023-12-31","value":-181200000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (1.05M) | (2.15M) | (1.05M) | (1.81M) | [{"date":"2020-12-31","value":-105135300,"profit":false},{"date":"2021-12-31","value":-214500000,"profit":false},{"date":"2022-12-31","value":-105000000,"profit":false},{"date":"2023-12-31","value":-181200000,"profit":false}] | |
EPS (Diluted) | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
KAPA | |
---|---|
Current Ratio | 0.02 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KAPA | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KAPA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.86 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KAPA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
EV/R | 0.00 |
EV/Ebitda | NM |
Kairos Pharma, Ltd. (KAPA) share price today is $2.097
Yes, Indians can buy shares of Kairos Pharma, Ltd. (KAPA) on Vested. To buy Kairos Pharma, Ltd. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KAPA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kairos Pharma, Ltd. (KAPA) via the Vested app. You can start investing in Kairos Pharma, Ltd. (KAPA) with a minimum investment of $1.
You can invest in shares of Kairos Pharma, Ltd. (KAPA) via Vested in three simple steps:
The 52-week high price of Kairos Pharma, Ltd. (KAPA) is $4. The 52-week low price of Kairos Pharma, Ltd. (KAPA) is $.
The price-to-earnings (P/E) ratio of Kairos Pharma, Ltd. (KAPA) is
The price-to-book (P/B) ratio of Kairos Pharma, Ltd. (KAPA) is 0.00
The dividend yield of Kairos Pharma, Ltd. (KAPA) is 0.00%
The market capitalization of Kairos Pharma, Ltd. (KAPA) is $25.43M
The stock symbol (or ticker) of Kairos Pharma, Ltd. is KAPA